Chris Ocampo
Head of Psychiatry, Neuroscience Clinical Development Abbvie
Seminars
Wednesday 16th September 2026
Panel Discussion: Overcoming the Phase 2/3 Roadblock in Neuropsychiatric Drug Development: What Have We Learnt in 2026?
8:00 am
- How late stage failures continue to stem from heterogeneous patient populations and poor endpoint sensitivity, underscoring the critical need for biomarker driven stratification to boost Phase 2/3 success rates
- What 2025–2026 taught us about placebo inflation, highlighted by recent schizophrenia and depression trial outcomes, and how study site variability, digital tools, and speech/physiological biomarkers may mitigate expectation bias
- Why translational gaps persist across muscarinic, psychedelic, and neuroplasticity based mechanisms, and how emerging mechanistic and genomic biomarkers can better link target engagement with clinical effects in Phase 2/3
- How sponsors are redesigning global Phase 2/3 execution—leveraging faster moving regions, adaptive designs, and early signal-detection: to overcome long timelines, recruitment bottlenecks, and historically low CNS trial success rates
Wednesday 16th September 2026
Panel Discussion: Neuropsychiatry at a Crossroads: Where Science, Strategy & Deal Making Converge
9:45 am
- What indications are you excited about and actively exploring?
- Which drug modalities are you excited about and actively exploring?
- In 2026 are we ready for precision psychiatry, and what might we need to improve in terms of diagnostics to get there (genetics, etc.)?
